UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 21, 2008 SPHERIX® INCORPORATED (Exact name of registrant as specified in its charter) 0-5576 Delaware 52-0849320 (State or other jurisdiction (Commission (I.R.S. Employer Identification No.) of incorporation) File Number) 6430 Rockledge Drive, Suite 503, Bethesda, MD 20817 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code 301-897-2540 Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): [] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 3 – Securities and Trading Markets.

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On July 21, 2008, Spherix Incorporated (the "Company") received written notification (the "Notice") from the NASDAQ Stock Market LLC ("NASDAQ") advising the Company that the bid price of the Company's common stock (the "Common Stock") for the last thirty (30) consecutive business days had closed below the minimum \$1.00 per share (the "Minimum Price Requirement") required for continued listing on the NASDAQ pursuant to NASDAQ Marketplace Rule 4450(a)(5) (the "Rule"). The Notice has no effect on the listing of the Common Stock at this time.

Pursuant to NASDAQ Marketplace Rule 4450(e)(2), the Company has been provided an initial period of 180 calendar days, or until January 20, 2009, to regain compliance with the Minimum Price Requirement. The Notice further provides that the NASDAQ staff (the "Staff") will provide written notification stating that the Company has achieved compliance with the Rule if at any time before January 20, 2009, the bid price of the Common Stock closes at \$1.00 per share or more for a minimum of ten (10) consecutive business days, although, under certain circumstances, the Staff has the discretion to require compliance for a period in excess of ten (10) consecutive business days, but generally such extended period does not exceed twenty (20) consecutive business days.

If the Company does not regain compliance with the Rule by January 20, 2009, NASDAQ will provide notice to the Company that the Common Stock will be delisted from NASDAQ. If the Company receives such a letter, the Company will have an opportunity to appeal the determination to a NASDAQ Listing Qualification Panel.

The Company is considering seeking stockholder approval for a reverse stock split to address the bid price deficiency.

As required by NASDAQ Marketplace Rule 4803(a), the Company has issued a press release dated July 23, 2008, reporting the receipt of the Notice and the NASDAQ rules upon which it is based. A copy of the press release is attached hereto as Exhibit 99.1 and the information contained herein is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Description

99.1 Press Release issued by July 23, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Spherix Incorporated (Registrant)

By:

/s/ Claire Kruger Claire Kruger CEO

Date: July 23, 2008

For additional information, contact Investor Relations, (301) 897-2540 Email: info@spherix.com

July 23, 2008

SPHERIX RECEIVES NASDAQ BID PRICE DEFICIENCY LETTER

BETHESDA, MD, Spherix Incorporated (NASDAQ/SPEX) reported that on July 21, 2008, it received written notification from NASDAQ advising the Company that the bid price of the Company's common stock for the last thirty (30) consecutive business days had closed below the minimum \$1.00 per share required for continued listing on NASDAQ. This notice has no effect on the listing of the Common Stock at this time.

Spherix has been provided an initial period of 180 calendar days, or until January 20, 2009, to regain compliance with the minimum price requirement. The notification further provides that NASDAQ will provide written notification stating that the Company has achieved compliance if at any time before January 20, 2009, the bid price of its common stock closes at \$1.00 per share or more for a minimum of ten (10) consecutive business days. Under certain circumstances, NASDAQ has the discretion to require compliance for a period in excess of ten (10) consecutive business days, but generally such extended period does not exceed twenty (20) consecutive business days.

If the Company does not regain compliance with this rule by January 20, 2009, NASDAQ will provide notice to the Company that its common stock will be delisted from NASDAQ. If the Company receives such a letter, the Company will have an opportunity to appeal the determination.

The Company is considering seeking stockholder approval for a reverse stock split to address the bid price deficiency.

Certain statements contained herein are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied. Factors that could cause actual results to differ materially from those expressed or implied include, but are not limited to, those discussed in filings by the Company with the Securities and Exchange Commission, including the filing on Form 8-K made on October 10, 2007.

Spherix's mission is to create value and increase shareholder wealth through innovations that benefit our clients and the human condition. Spherix offers innovations in biotechnology, and provides technical and regulatory consulting services to biotechnology and pharmaceutical companies.

Our Internet address is http://www.spherix.com.